Physician profile
Ritoo Jain
NPI 1487666509
$469.81
in general payments reported to CMS, 2019-2025
13 companies · $53.04 in 2025
The $53.04 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.75 · 2020: $43.36 · 2021: $22.40 · 2023: $183 · 2024: $98.71 · 2025: $53.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108.72 | 2023-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $82.78 | 2019-2023 | Farxiga |
| Pfizer INC. | $46.11 | 2024 | |
| Mylan Specialty L.P. | $39.56 | 2019-2024 | Yupelri |
| Novo Nordisk INC | $39.50 | 2020-2025 | Wegovy |
| Amgen INC. | $28.17 | 2019-2024 | Prolia, Evenity |
| Sanofi Pasteur INC. | $27.77 | 2019-2020 | |
| Optinose US, INC. | $22.40 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.55 | 2025 | Rexulti |
| Boston Scientific Corporation | $16.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.96 | 2025 | Xifaxan |
| Dexcom, INC. | $13.87 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $12.94 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritoo Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.